NEW YORK (GenomeWeb News) – Cancer biosampling company Indivumed said today that it has received certification from the International Organization for Standardization for its clinical data and research services and related biobanking products.
The ISO-9001:2008 certification covers all of Indivumed's processes, including quality levels for all tissues and other biospecimens, and it covers the company's preclinical and clinical services, such as identification of drug targets and other biomarkers, drug profiling, and quality management.
The Hamburg, Germany-based company integrates proprietary clinical and lab facilities with a biospecimen biobank of more than 11,000 samples, and it has a subsidiary operating in Maryland. It offers a range of immunohistochemistry services, drug profiling for primary tumor cultures, a biobank portfolio, and other research services.
To achieve the certification, Indivumed said it established a quality management system to cover all of its processes and it developed standard operating procedures including robust control mechanisms.
"Now, our customers can use our tissue, data and services to develop personalized cancer treatments in clinical trials, e.g. for the development of companion diagnostics to guide targeted therapeutics," Indivumed CEO Hartmut Juhl said in a statement.